UCB Announces Partnership With Microsoft To Expedite Treatment Options

Biopharmaceutical company UCB has entered a multi-year collaboration with technology company Microsoft to discover data-driven insights and produce effective treatments in immunology and neurology.

UCB looks to utilize Microsoft’s computing power and Artificial Intelligence (AI) capabilities. This partnership is an expansion of the company’s collaboration in the COVID Moonshot project in which an orally bioavailable antiviral is being developed.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The partnership will focus on four primary objectives which include improving the overall patient journey, creating a better understanding of the causes of disease, speeding discovery using data-driven insights, and accelerating clinical development timelines.

UCB CEO Jean-Christophe Tellier said, “By amplifying the power of scientific innovation through digital transformation, we hope to have a better understanding of what makes a patient’s journey unique so that we can provide personalized and differentiated medicine in a sustainable way.”

Throughout this collaboration, Microsoft applied scientists will work with UCB scientists and data specialists to utilize computational services and create tailored therapies and medications. Microsoft can offer the platform needed to analyze high-dimensional data sets and multi-modal unstructured information with its cloud and AI systems.

This partnership will also provide innovative insights for both immunology and neurology through continuous study of patient condition and disease causes and will speed up development in clinical trials. Combining Microsoft’s services with UCB’s specialists will result in individualized medicine and treatments. This partnership will also set a standard for future innovation by providing a platform that allows for high-dimensional data set and multi-modal unstructured information analysis.

Other biotechnology and pharmaceutical companies are chasing similar goals to reduce time needed to produce treatment options. Boehringer Ingelheim recently teamed up with Google in order to utilize its quantum computing capabilities alongside its molecular dynamic’s simulations.

Tech and pharmaceutical companies are racing to discover news ways of developing treatment options in the immunology and neurology fields by combining knowledge in biotechnology and data analysis.  These partnerships will meet the demand for increased computing power while in clinical trial phases and allow researchers to develop new, expedited, and personalized methods of research and production.